Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy

Lingmin He, Annie Chan, Theodore Leng, Mark S BlumenkranzDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, California, USABackground: The purpose of this study was to characterize central macular thickness and retinal volume following intravitreal injections using time d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	He L, Chan A, Leng T, Blumenkranz MS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/b12d293847fa482ab5773aca3ea3f75d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b12d293847fa482ab5773aca3ea3f75d
record_format	dspace
spelling	oai:doaj.org-article:b12d293847fa482ab5773aca3ea3f75d2021-12-02T05:35:06ZKinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy1177-54671177-5483https://doaj.org/article/b12d293847fa482ab5773aca3ea3f75d2011-12-01T00:00:00Zhttp://www.dovepress.com/kinetics-of-central-macular-thickness-reduction-in-patients-with-macul-a8841https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Lingmin He, Annie Chan, Theodore Leng, Mark S BlumenkranzDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, California, USABackground: The purpose of this study was to characterize central macular thickness and retinal volume following intravitreal injections using time domain and spectral domain optical coherence tomography (TD-OCT and SD-OCT, respectively).Methods: Nine patients with macular edema secondary to diabetes or retinal vein occlusion treated with intravitreal triamcinolone 4.0 mg and/or bevacizumab 1.25 mg were enrolled. Central macular thickness and volume was measured by SD-OCT and TD-OCT scan at baseline, and 1, 3, 6, 24, 48 hours, and 1 week postinjection.Results: Equations were derived to describe central macular thickness and volume reduction in the hours following intravitreal injection. Measurements of central macular thickness by SD-OCT were significantly reduced by 3 hours (P = 0.03) and retinal volume by 6 hours (P = 0.03). Central macular thickness measured 40.9 (28.6&ndash;53.2) &micro;m thicker on the SD-OCT instrument while volume measured 3.47 (3.27&ndash;3.66) mm3 higher.Conclusion: Significant central macular thickness and volume reductions occur in the first hours after injection with triamcinolone and/or bevacizumab.Keywords: retinal vein occlusion, intravitreal injection, diabetic retinopathyHe LChan ALeng TBlumenkranz MSDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 1751-1758 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 He L Chan A Leng T Blumenkranz MS Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy
description	Lingmin He, Annie Chan, Theodore Leng, Mark S BlumenkranzDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, California, USABackground: The purpose of this study was to characterize central macular thickness and retinal volume following intravitreal injections using time domain and spectral domain optical coherence tomography (TD-OCT and SD-OCT, respectively).Methods: Nine patients with macular edema secondary to diabetes or retinal vein occlusion treated with intravitreal triamcinolone 4.0 mg and/or bevacizumab 1.25 mg were enrolled. Central macular thickness and volume was measured by SD-OCT and TD-OCT scan at baseline, and 1, 3, 6, 24, 48 hours, and 1 week postinjection.Results: Equations were derived to describe central macular thickness and volume reduction in the hours following intravitreal injection. Measurements of central macular thickness by SD-OCT were significantly reduced by 3 hours (P = 0.03) and retinal volume by 6 hours (P = 0.03). Central macular thickness measured 40.9 (28.6&ndash;53.2) &micro;m thicker on the SD-OCT instrument while volume measured 3.47 (3.27&ndash;3.66) mm3 higher.Conclusion: Significant central macular thickness and volume reductions occur in the first hours after injection with triamcinolone and/or bevacizumab.Keywords: retinal vein occlusion, intravitreal injection, diabetic retinopathy
format	article
author	He L Chan A Leng T Blumenkranz MS
author_facet	He L Chan A Leng T Blumenkranz MS
author_sort	He L
title	Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy
title_short	Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy
title_full	Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy
title_fullStr	Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy
title_full_unstemmed	Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy
title_sort	kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/b12d293847fa482ab5773aca3ea3f75d
work_keys_str_mv	AT hel kineticsofcentralmacularthicknessreductioninpatientswithmacularedemaafterintravitrealdrugtherapy AT chana kineticsofcentralmacularthicknessreductioninpatientswithmacularedemaafterintravitrealdrugtherapy AT lengt kineticsofcentralmacularthicknessreductioninpatientswithmacularedemaafterintravitrealdrugtherapy AT blumenkranzms kineticsofcentralmacularthicknessreductioninpatientswithmacularedemaafterintravitrealdrugtherapy
_version_	1718400369380294656

Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy

Ejemplares similares